Abi-Dargham, 2004, Int J Neuropsychopharmacol, 7, s1, 10.1017/S1461145704004110
Abi-Dargham, 2000, Proc Natl Acad Sci USA, 97, 8104, 10.1073/pnas.97.14.8104
Accili, 1996, Proc Natl Acad Sci USA, 93, 1945, 10.1073/pnas.93.5.1945
Aiba, 1999, Nihon Shinkei Seishin Yakurigaku Zasshi, 19, 251
Akiyama, 1994, Schizophr Res, 12, 251, 10.1016/0920-9964(94)90035-3
Alburges, 1993, Synapse, 14, 314, 10.1002/syn.890140409
Allen, 1978, Am J Psychiatry, 135, 1081, 10.1176/ajp.135.9.1081
Andersen, 2001, Psychopharmacology (Berl), 156, 291, 10.1007/s002130100818
Arnold, 1991, Arch Gen Psychiatry, 48, 625, 10.1001/archpsyc.1991.01810310043008
Arnold, 1995, Am J Psychiatry, 152, 738, 10.1176/ajp.152.5.738
Atkinson, 2001, Mol Pharmacol, 60, 1414, 10.1124/mol.60.6.1414
Badner, 2002, Mol Psychiatry, 7, 405, 10.1038/sj.mp.4001012
Bai, 2004, Biol Psychiatry, 56, 427, 10.1016/j.biopsych.2004.06.022
Bast, 2000, Pharmacol Biochem Behav, 67, 647, 10.1016/S0091-3057(00)00409-3
Bast, 2001, Neuroscience, 103, 325, 10.1016/S0306-4522(00)00589-3
Bastia, 2005, Neuropsychopharmacology, 30, 891, 10.1038/sj.npp.1300630
Beaulieu, 2004, Proc Natl Acad Sci USA, 101, 5099, 10.1073/pnas.0307921101
Beaulieu, 2005, Cell, 122, 261, 10.1016/j.cell.2005.05.012
Benson, 2004, Trends Neurosci, 27, 516, 10.1016/j.tins.2004.06.004
Beraki, 2005, Mol Psychiatry, 10, 299, 10.1038/sj.mp.4001545
Bergson, 2003, Trends Pharmacol Sci, 24, 486, 10.1016/S0165-6147(03)00232-3
Bhardwaj, 2003, Neuroscience, 122, 669, 10.1016/j.neuroscience.2003.08.016
Birdsall, 1977, Adv Behav Biol, 24, 25, 10.1007/978-1-4684-3096-7_2
Blackwood, 2001, Am J Hum Genet, 69, 428, 10.1086/321969
Blumer, 2004, Nature, 427, 20, 10.1038/427020a
Boksa, 2003, Neurosci Biobehav Rev, 27, 91, 10.1016/S0149-7634(03)00012-5
Boksa, 2002, Exp Neurol, 175, 388, 10.1006/exnr.2002.7896
Bondy, 1987, J Psychiatr Res, 21, 521, 10.1016/0022-3956(87)90101-4
Brady, 1991, J Clin Psychiatry, 52, 509
Braff, 2005, Biol Psychiatry, 57, 817, 10.1016/j.biopsych.2004.12.030
Brandon, 1998, J Neurosci, 18, 3639, 10.1523/JNEUROSCI.18-10-03639.1998
Brody, 2004a, Psychopharmacology (Berl), 172, 187, 10.1007/s00213-003-1635-3
Brody, 2004b, Mol Psychiatry, 9, 35, 10.1038/sj.mp.4001404
Bronsert, 2001, Behav Pharmacol, 12, 549, 10.1097/00008877-200111000-00017
Brown, 2004, Arch Gen Psychiatry, 61, 774, 10.1001/archpsyc.61.8.774
Brzustowicz, 2000, Science, 288, 678, 10.1126/science.288.5466.678
Burchett, 1998, J Neurochem, 70, 2216, 10.1046/j.1471-4159.1998.70052216.x
Burchett, 1999, J Neurochem, 72, 1529, 10.1046/j.1471-4159.1999.721529.x
Butkerait, 1994, J Pharmacol Exp Ther, 271, 422
Cabrera-Vera, 2004, Proc Natl Acad Sci USA, 101, 16339, 10.1073/pnas.0407416101
Cadenhead, 2000, Am J Psychiatry, 157, 1660, 10.1176/appi.ajp.157.10.1660
Cardno, 2001, Am J Med Genet, 105, 439, 10.1002/ajmg.1404
Carey, 1999, Am J Med Genet, 89, 7, 10.1002/(SICI)1096-8628(19990326)89:1<7::AID-AJMG4>3.0.CO;2-#
Carrasco, 2004, J Pharmacol Exp Ther, 311, 349, 10.1124/jpet.104.069807
Carta, 2000, Neuroreport, 11, 2395, 10.1097/00001756-200008030-00012
Chartoff, 2005, Neuropsychopharmacology, 30, 1324, 10.1038/sj.npp.1300678
, , , , , et al. 2004. Behavioral deficits of ERK1 knockout mice in mood disorder-related animal tests [Abstracts]. In: The 43rd Annual Meeting of American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12–16, 2004.
, . 2005. New genetic mouse models of schizophrenia: Mimicking cognitive dysfunction by altering susceptibility gene expression (Program No. TUAM65). Abstract viewer. Waikoloa, HI: American College of Neuropsychopharmacology.
Chen, 2000, Neuroscience, 97, 195, 10.1016/S0306-4522(99)00604-1
Chen, 2003, Neuropsychopharmacology, 28, 1086, 10.1038/sj.npp.1300152
Chiamulera, 2001, Nat Neurosci, 4, 873, 10.1038/nn0901-873
Chidiac, 1997, Biochemistry, 36, 7361, 10.1021/bi961939t
Chouinard, 1991, Schizophr Res, 5, 21, 10.1016/0920-9964(91)90050-2
Chouinard, 1978, Am J Psychiatry, 135, 1409, 10.1176/ajp.135.11.1409
Chowdari, 2002, Hum Mol Genet, 11, 1373, 10.1093/hmg/11.12.1373
Chumakov, 2002, Proc Natl Acad Sci USA, 99, 13675, 10.1073/pnas.182412499
Coccini, 1991, Immunopharmacology, 22, 93, 10.1016/0162-3109(91)90034-V
Collier, 2003, Eur J Pharmacol, 480, 177, 10.1016/j.ejphar.2003.08.105
Colussi-Mas, 2005, Int J Neuropsychopharmacol, 8, 569, 10.1017/S1461145705005298
Corripio, 2006, Neuroimage, 29, 662, 10.1016/j.neuroimage.2005.07.038
Craddock, 2005, J Med Genet, 42, 193, 10.1136/jmg.2005.030718
Crawford, 1997, Neuroreport, 8, 2523, 10.1097/00001756-199707280-00021
Curran, 2004, Br J Psychiatry, 185, 196, 10.1192/bjp.185.3.196
De Lean, 1980, J Biol Chem, 255, 7108, 10.1016/S0021-9258(20)79672-9
DeLisi, 1997, Psychiatry Res, 74, 129, 10.1016/S0925-4927(97)00012-7
Depoortère, 2005, Neuropsychopharmacology, 30, 1963, 10.1038/sj.npp.1300772
Deroche, 1995, J Neurosci, 15, 7181, 10.1523/JNEUROSCI.15-11-07181.1995
Dewey, 1983, Naunyn-Schmiedebergs Arch Pharmacol, 322, 261, 10.1007/BF00508341
Doudet, 2000, Synapse, 38, 105, 10.1002/1098-2396(200011)38:2<105::AID-SYN1>3.0.CO;2-S
Dubertret, 2004, Schizophr Res, 67, 75, 10.1016/S0920-9964(03)00220-2
Dulawa, 2000, Neuropsychopharmacology, 22, 650, 10.1016/S0893-133X(99)00164-5
Duncan, 2003a, Psychopharmacology (Berl), 167, 63, 10.1007/s00213-002-1372-z
Duncan, 2003b, Psychiatry Res, 120, 1, 10.1016/S0165-1781(03)00161-6
Egan, 1997, Curr Opin Neurobiol, 7, 701, 10.1016/S0959-4388(97)80092-X
Egan, 2004, Proc Natl Acad Sci USA, 101, 12604, 10.1073/pnas.0405077101
Ekelund, 2001, Hum Mol Genet, 10, 1611, 10.1093/hmg/10.15.1611
El-Ghundi, 2001, Brain Res, 892, 86, 10.1016/S0006-8993(00)03234-0
El-Khodor, 1998, Neuroscience, 87, 893, 10.1016/S0306-4522(98)00194-8
Emamian, 2004, Nat Genet, 36, 131, 10.1038/ng1296
Feifel, 1999, Psychopharmacology (Berl), 146, 175, 10.1007/s002130051103
Feifel, 2004, Neuropsychopharmacology, 29, 731, 10.1038/sj.npp.1300378
Ferguson, 2001, Pharmacol Rev, 53, 1
Flores, 1996a, J Neurosci, 16, 2020, 10.1523/JNEUROSCI.16-06-02020.1996
Flores, 1996b, J Neurosci, 16, 7366, 10.1523/JNEUROSCI.16-22-07366.1996
Friberg, 1998, Brain Res Mol Brain Res, 54, 298, 10.1016/S0169-328X(97)00346-X
Fritts, 1997, Pharmacol Biochem Behav, 58, 1015, 10.1016/S0091-3057(97)00308-0
Gabriel, 2002, Nat Genet, 31, 89, 10.1038/ng868
Gainetdinov, 2003, Neuron, 38, 291, 10.1016/S0896-6273(03)00192-2
Gainetdinov, 2004, Annu Rev Neurosci, 27, 107, 10.1146/annurev.neuro.27.070203.144206
George, 1985, Endocrinology, 117, 690, 10.1210/endo-117-2-690
Geuze, 2005, Mol Psychiatry, 10, 160, 10.1038/sj.mp.4001579
Giannini, 1984, J Clin Pharmacol, 24, 202, 10.1002/j.1552-4604.1984.tb01831.x
Giannini, 1984–85, J Toxicol Clin Toxicol, 22, 573, 10.3109/15563658408992586
Glatt, 2006, Am J Med Genet B Neuropsychiatr Genet, 141, 149, 10.1002/ajmg.b.30273
Glatt, 2003, Mol Psychiatry, 8, 911, 10.1038/sj.mp.4001321
, , , , , , , . 2005. Frontal dopamine D2 receptor binding in neuroleptic-naïve first-episode schizophrenic patients correlates with positive psychotic symptoms and predicts treatment outcome (Program No. 19). Abstract viewer. Waikoloa, HI: American College of Neuropsychopharmacology.
Glickstein, 2001, Pharmacol Ther, 91, 63, 10.1016/S0163-7258(01)00145-0
Goff, 2001, Am J Psychiatry, 158, 1367, 10.1176/appi.ajp.158.9.1367
Gold, 1997, J Neurosci, 17, 8024, 10.1523/JNEUROSCI.17-20-08024.1997
Gourianov, 2005, Biochemistry, 44, 14989, 10.1021/bi0513812
Graham, 2004, J Psychopharmacol, 18, 173, 10.1177/0269881104042615
Green, 1997, Biochemistry, 36, 7380, 10.1021/bi961940s
Greenberg, 1985, Pharmacol Biochem Behav, 23, 99, 10.1016/0091-3057(85)90137-6
Grillet, 2005, Mol Cell Biol, 25, 4221, 10.1128/MCB.25.10.4221-4228.2005
Guillin, 2001, Nature, 411, 86, 10.1038/35075076
Hall, 1987, Pharmacol Toxicol, 60, 359, 10.1111/j.1600-0773.1987.tb01527.x
Harrison, 2003, Lancet, 361, 417, 10.1016/S0140-6736(03)12379-3
Harrison, 2005, Mol Psychiatry, 10, 40, 10.1038/sj.mp.4001558
Hashimoto, 2004, Curr Med Chem Cent Nerv Syst Agents, 4, 147, 10.2174/1568015043357011
, , . 2005. Identification and characterization of D2 dopamine receptor-interacting proteins. (Program No. 33.9). Abstract viewer/Itinerary planner. Washington, DC: Society for Neuroscience.
Heldt, 2004, Neuropsychopharmacology, 29, 1610, 10.1038/sj.npp.1300468
Herrmann, 2004, J Biol Chem, 279, 24283, 10.1074/jbc.M311166200
Hersch, 1995, J Neurosci, 15, 5222, 10.1523/JNEUROSCI.15-07-05222.1995
Hirvonen, 2005, Arch Gen Psychiatry, 62, 371, 10.1001/archpsyc.62.4.371
Holmes, 2001, Behav Neurosci, 115, 1129, 10.1037/0735-7044.115.5.1129
Holmes, 2004, Neuropharmacology, 47, 1117, 10.1016/j.neuropharm.2004.07.034
Holzman, 1988, Arch Gen Psychiatry, 45, 641, 10.1001/archpsyc.1988.01800310049006
Houchi, 2005, Neuropsychopharmacology, 30, 339, 10.1038/sj.npp.1300568
Hu, 2002, Proc Natl Acad Sci USA, 99, 9755, 10.1073/pnas.152094799
Huotari, 2002, Eur J Neurosci, 15, 246, 10.1046/j.0953-816x.2001.01856.x
Huotari, 2004, Psychopharmacology, 172, 1, 10.1007/s00213-003-1627-3
Ikeda, 2005, Am J Med Genet B Neuropsychiatr Genet, 134, 90, 10.1002/ajmg.b.30155
Ingi, 1998, J Neurosci, 18, 7178, 10.1523/JNEUROSCI.18-18-07178.1998
Itzhak, 2000, Psychopharmacology (Berl), 151, 226, 10.1007/s002130000394
Iwabuchi, 2004, Ann N Y Acad Sci, 1025, 129, 10.1196/annals.1316.016
Jacob, 1986, J Neural Transm, 65, 303, 10.1007/BF01249090
Jacob, 1994, J Neural Transm, 98, 83, 10.1007/BF01277013
James, 2004, Mol Cell Neurosci, 26, 112, 10.1016/j.mcn.2004.01.013
Janowsky, 1977, Arch Gen Psychiatry, 34, 189, 10.1001/archpsyc.1977.01770140079009
Jaskiw, 1990, Brain Res, 534, 263, 10.1016/0006-8993(90)90138-2
Jenner, 1982, Biochem Pharmacol, 31, 325, 10.1016/0006-2952(82)90178-2
Jonsson, 1999, Schizophr Res, 40, 31, 10.1016/S0920-9964(99)00033-X
Jonsson, 2003, Am J Med Genet B Neuropsychiatr Genet, 119, 28, 10.1002/ajmg.b.20004
Juárez, 2005, Synapse, 58, 236, 10.1002/syn.20203
Juhila, 2005, Eur J Pharmacol, 517, 74, 10.1016/j.ejphar.2005.05.022
Kabbani, 2002, J Neurosci, 22, 8476, 10.1523/JNEUROSCI.22-19-08476.2002
Kapur, 2002, Mol Psychiatry, 7, 837, 10.1038/sj.mp.4001093
Kapur, 2003, J Pharmacol Exp Ther, 305, 625, 10.1124/jpet.102.046987
Karasinska, 2005, Eur J Neurosci, 22, 1741, 10.1111/j.1460-9568.2005.04353.x
Karper, 2002, Psychopharmacology, 159, 407, 10.1007/s00213-001-0936-7
Kathmann, 2003, Am J Psychiatry, 160, 696, 10.1176/appi.ajp.160.4.696
Kellendonk, 2006, Neuron, 49, 603, 10.1016/j.neuron.2006.01.023
Kim, 2000, J Neurosci, 20, 4405, 10.1523/JNEUROSCI.20-12-04405.2000
Kim, 2002, Pharmacol Biochem Behav, 73, 333, 10.1016/S0091-3057(02)00827-4
King, 1994, J Pharmacol Exp Ther, 269, 743
Kirkpatrick, 1992, J Nerv Ment Dis, 180, 265, 10.1097/00005053-199204000-00009
Ko, 2002, Neuroreport, 13, 1017, 10.1097/00001756-200206120-00007
Koh, 2003, Proc Natl Acad Sci USA, 100, 313, 10.1073/pnas.232693499
Kovoor, 2005, J Neurosci, 25, 2157, 10.1523/JNEUROSCI.2840-04.2005
Kruzich, 2004, Synapse, 53, 131, 10.1002/syn.20043
Krystal, 2005, Arch Gen Psychiatry, 62, 985, 10.1001/archpsyc.62.9.985
Kubota, 2002, J Neurochem, 83, 837, 10.1046/j.1471-4159.2002.01189.x
Kumari, 1998, Behav Pharmacol, 9, 567, 10.1097/00008877-199811000-00012
Kumari, 2004, Schizophr Res, 69, 219, 10.1016/j.schres.2003.09.010
Kuribara, 1995, Psychopharmacology (Berl), 119, 34, 10.1007/BF02246051
Lähdesmäki, 2004, Neuropsychopharmacology, 29, 1282, 10.1038/sj.npp.1300428
LaHoste, 1992, Synapse, 12, 14, 10.1002/syn.890120103
Lahti, 2001, Neuropsychopharmacology, 25, 455, 10.1016/S0893-133X(01)00243-3
Lawford, 2005, Schizophr Res, 73, 31, 10.1016/j.schres.2004.08.020
Le Moine, 1995, J Comp Neurol, 355, 418, 10.1002/cne.903550308
Le Pen, 2002, Neuropsychopharmacology, 27, 1, 10.1016/S0893-133X(01)00383-9
Lee, 2004, J Biol Chem, 279, 35671, 10.1074/jbc.M401923200
Levinson, 2002, Science, 296, 739, 10.1126/science.1069914
Lewis, 2003, Am J Hum Genet, 73, 34, 10.1086/376549
Lieberman, 1987, Psychopharmacology, 91, 415, 10.1007/BF00216006
Lieberman, 1990, Schizophr Bull, 16, 97, 10.1093/schbul/16.1.97
Lieberman, 2001, Biol Psychiatry, 49, 487, 10.1016/S0006-3223(01)01067-8
Lillrank, 1999, Neurochem Int, 34, 235, 10.1016/S0197-0186(99)00008-X
Lipska, 1993, Brain Res Dev Brain Res, 75, 213, 10.1016/0165-3806(93)90026-7
Lipska, 1991, Pharmacol Biochem Behav, 40, 181, 10.1016/0091-3057(91)90342-Y
Lipska, 1993, Neuropsychopharmacology, 9, 67, 10.1038/npp.1993.44
Lipska, 2003, Eur J Neurosci, 18, 3097, 10.1111/j.1460-9568.2003.03047.x
Lomanowska, 2004, Pharmacol Biochem Behav, 77, 617, 10.1016/j.pbb.2003.12.018
Lu, 2002, Ann Pharmacother, 36, 1387, 10.1345/aph.1A440
Ludewig, 2003, Biol Psychiatry, 54, 121, 10.1016/S0006-3223(02)01925-X
Macey, 2004, Mol Pharmacol, 66, 1635, 10.1124/mol.104.001495
MacKenzie, 1984, J Neurochem, 43, 1310, 10.1111/j.1471-4159.1984.tb05388.x
Mackeprang, 2002, Biol Psychiatry, 52, 863, 10.1016/S0006-3223(02)01409-9
Mandel, 1993, Behav Brain Res, 59, 53, 10.1016/0166-4328(93)90151-F
Martin, 2000, Eur J Neurosci, 12, 4038, 10.1046/j.1460-9568.2000.00287.x
Martinez, 2002, Psychopharmacology (Berl), 161, 38, 10.1007/s00213-001-0977-y
Matthysse, 2004, Am J Med Genet B Neuropsychiatr Genet, 128, 30, 10.1002/ajmg.b.30030
Mattingly, 1996, Pharmacol Biochem Behav, 53, 481, 10.1016/0091-3057(95)02101-9
Mattsson, 2004, Neuroscience, 127, 579, 10.1016/j.neuroscience.2004.05.038
Maziade, 2001, Mol Psychiatry, 6, 684, 10.1038/sj.mp.4000915
McDonald, 1984, Mol Cell Endocrinol, 36, 201, 10.1016/0303-7207(84)90037-6
McGorry, 2002, Arch Gen Psychiatry, 59, 921, 10.1001/archpsyc.59.10.921
McGuffin, 2003, Curr Psychiatry Rep, 5, 121, 10.1007/s11920-003-0028-y
McNeil, 2000, Am J Psychiatry, 157, 203, 10.1176/appi.ajp.157.2.203
Meincke, 2004a, Psychiatry Res, 126, 51, 10.1016/j.psychres.2004.01.003
Meincke, 2004b, Eur Arch Psychiatry Clin Neurosci, 254, 415, 10.1007/s00406-004-0523-0
Meller, 1996, Neuropharmacology, 35, 1785, 10.1016/S0028-3908(96)00119-0
Meng, 1998, Brain Res Mol Brain Res, 61, 39, 10.1016/S0169-328X(98)00196-X
Mileson, 1991, Brain Res, 561, 1, 10.1016/0006-8993(91)90742-E
Millar, 2000, Hum Mol Genet, 9, 1415, 10.1093/hmg/9.9.1415
Millar, 2003, Genetics, 163, 833, 10.1093/genetics/163.2.833
Mirnics, 2001, Mol Psychiatry, 6, 293, 10.1038/sj.mp.4000866
Miyakawa, 2003, Proc Natl Acad Sci USA, 100, 8987, 10.1073/pnas.1432926100
Miyamoto, 2005, Mol Psychiatry, 10, 79, 10.1038/sj.mp.4001556
Morishima, 2005, Proc Natl Acad Sci USA, 102, 4170, 10.1073/pnas.0500914102
Morris, 2005, Curr Opin Pharmacol, 5, 101, 10.1016/j.coph.2004.08.008
Morris, 2003, Schizophr Res, 60, 167, 10.1016/S0920-9964(02)00527-3
Mowry, 2004, Mol Psychiatry, 9, 784, 10.1038/sj.mp.4001481
Mueller, 2004, Schizophr Res, 71, 361, 10.1016/j.schres.2004.02.016
Naber, 1982, Biochem Biophys Res Commun, 107, 374, 10.1016/0006-291X(82)91714-4
Nadri, 2004, Schizophr Res, 71, 377, 10.1016/j.schres.2004.02.020
Nelson, 1998, Arch Gen Psychiatry, 55, 433, 10.1001/archpsyc.55.5.433
Neubig, 2002, J Peptide Res, 60, 312, 10.1034/j.1399-3011.2002.21064.x
Neubig, 2002, Nat Rev Drug Discov, 11, 187, 10.1038/nrd747
Neves-Pereira, 2005, Mol Psychiatry, 10, 208, 10.1038/sj.mp.4001575
Nishiguchi, 2004, Nature, 427, 75, 10.1038/nature02170
Nordström, 1995, Psychiatry Res, 61, 67, 10.1016/0925-4927(95)02732-D
Ögren, 1994, Neuropsychopharmacology, 11, 167, 10.1038/sj.npp.1380103
Oranje, 2002, JClin Psychopharmacol, 22, 359, 10.1097/00004714-200208000-00005
. 1984. Neurons containing or accumulating transmitter amino acids. In: , , editors. Handbook of chemical neuroanatomy, Vol. 3. Amsterdam: Elsevier. pp 141–286.
Owen, 2005, Trends Genet, 21, 518, 10.1016/j.tig.2005.06.011
Palmatier, 2004, Mol Psychiatry, 9, 859, 10.1038/sj.mp.4001496
Papiol, 2005, Neuroimage, 27, 1002, 10.1016/j.neuroimage.2005.05.035
Paterlini, 2005, Nat Neurosci, 8, 1586, 10.1038/nn1562
Perreault, 2005, Neuropsychopharmacology
Perrine, 2005, Brain Res Mol Brain Res, 133, 224, 10.1016/j.molbrainres.2004.10.025
Phillips, 2001, J Pharmacol Exp Ther, 296, 905
Pierre, 1998, Psychopharmacology (Berl), 138, 159, 10.1007/s002130050658
Pippig, 1993, J Biol Chem, 268, 3201, 10.1016/S0021-9258(18)53678-4
Posner, 1994, Mol Pharmacol, 45, 65
Powell, 2004, Neuron, 42, 143, 10.1016/S0896-6273(04)00146-1
Prien, 1969, Br J Psychiatry, 115, 679, 10.1192/bjp.115.523.679
Przegalinski, 2000, J Physiol Pharmacol (Poland), 51, 193
Rahman, 2003, Neuron, 38, 941, 10.1016/S0896-6273(03)00321-0
Ralph, 1999, J Neurosci, 19, 4627, 10.1523/JNEUROSCI.19-11-04627.1999
Ralph-Williams, 2002, J Neurosci, 22, 9604, 10.1523/JNEUROSCI.22-21-09604.2002
Ralph-Williams, 2003, Neuropsychopharmacology, 28, 108, 10.1038/sj.npp.1300017
Randall, 1985, Life Sci, 37, 1419, 10.1016/0024-3205(85)90081-5
Rao, 1990, Pharmacopsychiatry, 23, 176, 10.1055/s-2007-1014503
Resnick, 1999, J Neurochem, 73, 1539, 10.1046/j.1471-4159.1999.0731539.x
Richfield, 1989, Neuroscience, 30, 767, 10.1016/0306-4522(89)90168-1
Richtand, 2000, Brain Res, 867, 239, 10.1016/S0006-8993(00)02247-2
Richtand, 2006, Neuropsychopharmacology, 31, 77, 10.1038/sj.npp.1300791
Roberts, 2004, Mol Pharmacol, 66, 1573, 10.1124/mol.104.004077
Robinson, 2004, Proc Natl Acad Sci USA, 101, 13329, 10.1073/pnas.0405084101
Robinson, 1986, Brain Res Rev, 11, 157, 10.1016/0165-0173(86)90002-0
Robinson, 2000, Addiction, 95, s91, 10.1046/j.1360-0443.95.8s2.19.x
Rubinstein, 1997, Cell, 90, 991, 10.1016/S0092-8674(00)80365-7
Russig, 2004, Psychopharmacology (Berl), 175, 143, 10.1007/s00213-004-1810-1
Schank, 2005, Neuropsychopharmacology
Schlüter, 2003, Neuroscience, 118, 985, 10.1016/S0306-4522(03)00036-8
Schooler, 1967, Am J Psychiatry, 123, 986, 10.1176/ajp.123.8.986
Schroeder, 1999, Psychopharmacology (Berl), 145, 61, 10.1007/s002130051032
Schwarting, 1996, Prog Neurobiol, 49, 215, 10.1016/S0301-0082(96)00015-9
Seeger, 1982, Psychopharmacology, 76, 182, 10.1007/BF00435275
Seeman, 1974, Fed Proc, 33, 2116
Seeman, 1980, Pharmacol Rev, 32, 229
Seeman, 1987, Synapse, 1, 133, 10.1002/syn.890010203
Seeman, 2001, Clin Neurosci Res, 1, 53, 10.1016/S1566-2772(00)00007-4
Seeman, 2002, Can J Psychiatry, 47, 27, 10.1177/070674370204700106
Seeman, 2004, Science, 305, 180, 10.1126/science.1096072
Seeman, 2005, Am J Psychiatry, 162, 1984, 10.1176/appi.ajp.162.10.1984-a
Seeman, 2000, Proc Natl Acad Sci USA, 97, 7673, 10.1073/pnas.97.14.7673
Seeman, 2003, Synapse, 50, 35, 10.1002/syn.10221
Seeman, 2005, Synapse, 58, 122, 10.1002/syn.20193
Seeman, 2005, Synapse, 58, 275, 10.1002/syn.20210
Seeman, 1998, Mol Psychiatry, 3, 386, 10.1038/sj.mp.4000421
Seeman, 1999, Am J Psychiatry, 156, 876, 10.1176/ajp.156.6.876
Seeman, 1973, J Cell Biol, 56, 519, 10.1083/jcb.56.2.519
Seeman, 1974, Fed Proc, 33, 246
Seeman, 1975, Proc Natl Acad Sci USA, 72, 4376, 10.1073/pnas.72.11.4376
Seeman, 1976, Nature, 261, 717, 10.1038/261717a0
Seeman, 1984, J Neurochem, 43, 221, 10.1111/j.1471-4159.1984.tb06700.x
Seeman, 1985, Mol Pharmacol, 28, 391
Seeman, 1987, Neuropsychopharmacology, 1, 5, 10.1016/0893-133X(87)90004-2
Seeman, 1989, Proc Natl Acad Sci USA, 86, 10156, 10.1073/pnas.86.24.10156
Seeman, 1993, Synapse, 14, 254, 10.1002/syn.890140403
Seeman, 2002, Synapse, 46, 235, 10.1002/syn.10139
Seeman, 2003, Synapse, 49, 209, 10.1002/syn.10232
Seeman, 2004, Synapse, 52, 77, 10.1002/syn.20005
Seeman, 2005a, Mol Psychiatry, 10, 877, 10.1038/sj.mp.4001682
Seeman, 2005b, Proc Natl Acad Sci USA, 102, 3513, 10.1073/pnas.0409766102
Sesack, 2003, Ann N Y Acad Sci, 1003, 36, 10.1196/annals.1300.066
Sharifi, 2004, Neuroreport, 15, 2433, 10.1097/00001756-200410250-00026
Sibley, 1999, Annu Rev Pharmacol Toxicol, 39, 313, 10.1146/annurev.pharmtox.39.1.313
Siderovski, 1999, Crit Rev Biochem Mol Biol, 34, 215, 10.1080/10409239991209273
Smith, 2005, J Neurosci, 25, 914, 10.1523/JNEUROSCI.4079-04.2005
Smith, 1975, Psychopharmacol Commun, 1, 285
Soyka, 1994, J Stud Alcohol, 55, 503, 10.15288/jsa.1994.55.503
Sporn, 2005, Schizophr Res, 73, 243, 10.1016/j.schres.2004.07.020
Stadel, 1981, J Cyclic Nucleotide Res, 7, 37
St Clair, 1990, Lancet, 336, 13, 10.1016/0140-6736(90)91520-K
Stefansson, 2002, Am J Hum Genet, 71, 877, 10.1086/342734
, , , , , et al. 2004. NRG1 and other genes affecting the glutamatergic system conferring susceptibility to schizophrenia (Abstracts). In: The 43rd Annual Meeting of American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12–16, 2004. Available at 43:acnp.abstractcentral.com/planner.
Steiner, 1999, Proc Natl Acad Sci USA, 96, 5786, 10.1073/pnas.96.10.5786
Stéphane, 2005, Curr Psychiatry Rev, 1, 23, 10.2174/1573400052953583
Strakowski, 1996, Biol Psychiatry, 40, 872, 10.1016/0006-3223(95)00497-1
Strakowski, 1997, Biol Psychiatry, 42, 749, 10.1016/S0006-3223(97)00052-8
Sum, 2001, Biochem Pharmacol, 62, 829, 10.1016/S0006-2952(01)00819-X
Sumiyoshi, 2004, Neurosci Lett, 364, 124, 10.1016/j.neulet.2004.04.027
Sumiyoshi, 2005, Brain Res Mol Brain Res, 140, 116, 10.1016/j.molbrainres.2005.07.001
Surmeier, 1996, J Neurosci, 16, 6579, 10.1523/JNEUROSCI.16-20-06579.1996
Suzuki, 1997, Prog Neuropsychopharmacol Biol Psychiatry, 21, 359, 10.1016/S0278-5846(97)00006-7
Szechtman, 2001, BMC Neurosci, 2, 4, 10.1186/1471-2202-2-4
Takahashi, 1997, Proc Natl Acad Sci USA, 94, 9938, 10.1073/pnas.94.18.9938
Talbot, 2004, J Clin Invest, 113, 1353, 10.1172/JCI200420425
Tamminga, 2005, Mol Psychiatry, 10, 27, 10.1038/sj.mp.4001563
Taymans, 2003, J Neurochem, 84, 1118, 10.1046/j.1471-4159.2003.01610.x
Taymans, 2004, Eur J Neurosci, 19, 2249, 10.1111/j.0953-816X.2004.03336.x
Tenn, 2003, Schizophrenia Res, 64, 103, 10.1016/S0920-9964(03)00009-4
Tenn, 2005, Biol Psychiatry, 57, 586, 10.1016/j.biopsych.2004.12.013
Tepest, 2003, Biol Psychiatry, 54, 1234, 10.1016/S0006-3223(03)00702-9
Thiselton, 2004, Mol Psychiatry, 9, 777, 10.1038/sj.mp.4001530
Thomsen, 1988, Mol Pharmacol, 34, 814
Torrey, 2005, Biol Psychiatry, 57, 252, 10.1016/j.biopsych.2004.10.019
Traynor, 2005, Mol Interv, 5, 30, 10.1124/mi.5.1.7
Tsutsumi, 1995, Clin Neuropharmacol, 18, 64, 10.1097/00002826-199502000-00008
Tune, 1993, Psychiatry Res, 49, 219, 10.1016/0165-1781(93)90063-M
Tuominen, 2005, Schizophr Res, 72, 225, 10.1016/j.schres.2004.05.005
Uehara, 2000, Brain Res, 860, 77, 10.1016/S0006-8993(00)01985-5
Ujike, 2002, Curr Psychiatry Rep, 4, 177, 10.1007/s11920-002-0024-7
Ujike, 1990, Psychopharmacology (Berl), 102, 459, 10.1007/BF02247125
Usiello, 2000, Nature, 408, 199, 10.1038/35041572
Vekovischeva, 2001, J Neurosci, 21, 4451, 10.1523/JNEUROSCI.21-12-04451.2001
Vezina, 1996, J Neurosci, 16, 2411, 10.1523/JNEUROSCI.16-07-02411.1996
Vile, 1996, Biol Psychiatry, 40, 881, 10.1016/0006-3223(95)00498-X
Virgos, 2001, Schizophr Res, 49, 65, 10.1016/S0920-9964(00)00106-7
Volkow, 2001, Am J Psychiatry, 158, 2015, 10.1176/appi.ajp.158.12.2015
VonVoigtlander, 1975, J Pharmacol Exper Ther, 193, 88
Wan, 1997, Neuropsychopharmacology, 16, 259, 10.1016/S0893-133X(96)00217-5
Wan, 1996, Behav Brain Res, 78, 211, 10.1016/0166-4328(95)00251-0
Wang, 1997, Neuron, 19, 1285, 10.1016/S0896-6273(00)80419-5
Weinberger, 2001, Biol Psychiatry, 50, 825, 10.1016/S0006-3223(01)01252-5
Weinshenker, 2002, Proc Natl Acad Sci USA, 99, 13873, 10.1073/pnas.212519999
Whitaker, 2004, Med Hypotheses, 62, 5, 10.1016/S0306-9877(03)00293-7
Willeit, 2006, Biol Psychiatry, 59, 389, 10.1016/j.biopsych.2005.09.017
Williams, 2004, Biol Psychiatry, 55, 192, 10.1016/j.biopsych.2003.11.002
Wilson, 2005, J Med Chem, 48, 4153, 10.1021/jm050155n
Winterer, 2004, Trends Neurosci, 27, 683, 10.1016/j.tins.2004.08.002
, , , , . 2004. Deficit in prepulse inhibition and enhanced sensitivity to amphetamine in mice lacking the trace amine-1 receptor. [Abstracts]. In: The 43rd Meeting of American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12–16, 2004. Available at http://acnp.abstractcentral.com/planner.
Wong, 1997, J Cereb Blood Flow Metab, 17, 331, 10.1097/00004647-199703000-00010
Wood, 1997, Brain Res Dev Brain Res, 101, 17, 10.1016/S0165-3806(97)00050-3
Wreggett, 1995, J Biol Chem, 270, 22488, 10.1074/jbc.270.38.22488
Wyatt, 1988, Schizophr Res, 1, 3, 10.1016/0920-9964(88)90034-5
Wynn, 2004, Biol Psychiatry, 55, 518, 10.1016/j.biopsych.2003.10.018
Xu, 2000a, Nat Neurosci, 3, 465, 10.1038/74839
Xu, 1994, Cell, 79, 945, 10.1016/0092-8674(94)90026-4
Xu, 1997, Neuron, 19, 837, 10.1016/S0896-6273(00)80965-4
Xu, 1999, J Biol Chem, 274, 3549, 10.1074/jbc.274.6.3549
Xu, 2000b, Brain Res, 852, 198, 10.1016/S0006-8993(99)02258-1
Yao, 2004, Neuron, 41, 625, 10.1016/S0896-6273(04)00048-0
Yee, 2005, Proc Natl Acad Sci USA, 102, 17154, 10.1073/pnas.0508752102
Yui, 1999, Mol Psychiatry, 4, 512, 10.1038/sj.mp.4000575
Yurek, 2004, Brain Res, 1028, 116, 10.1016/j.brainres.2004.08.066
Zachariou, 2003, Proc Natl Acad Sci USA, 100, 13656, 10.1073/pnas.2232594100
Zhang, 1999, Gene, 240, 23, 10.1016/S0378-1119(99)00393-5
Zhou, 1995, Cell, 83, 1197, 10.1016/0092-8674(95)90145-0
Zhuang, 2001, Proc Natl Acad Sci USA, 98, 1982, 10.1073/pnas.98.4.1982
